Search Result

Results for "

Abl kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bcr-Abl (116) AAK1 (1) Ack1 (1) Akt (4) Antibiotic (1) Apoptosis (25) Aurora Kinase (13) Autophagy (28) Bacterial (1) Btk (1) c-Fms (1) c-Kit (15) c-Met/HGFR (2) c-Myc (1) CaMK (1) Casein Kinase (1) Caspase (1) CDK (2) Collagen (1) Cyclin G-associated Kinase (GAK) (1) Discoidin Domain Receptor (2) DNA-PK (1) Drug Metabolite (3) DYRK (1) EGFR (5) Ephrin Receptor (3) ERK (1) Ferroptosis (2) FGFR (9) FLT3 (10) GSK-3 (2) Histone Methyltransferase (1) IGF-1R (1) Isotope-Labeled Compounds (6) JAK (10) LIM Kinase (LIMK) (2) LRRK2 (1) MAP4K (2) MAPKAPK2 (MK2) (1) Microtubule/Tubulin (1) MNK (1) mTOR (1) NF-κB (1) P-glycoprotein (1) p38 MAPK (3) PARP (1) PDGFR (22) PERK (1) PI3K (1) PKD (2) Prion Protein (3) PROTACs (3) Pyk2 (1) Raf (2) Reference Standards (15) RET (2) Salt-inducible Kinase (SIK) (2) SARS-CoV (6) Src (35) STAT (10) TAM Receptor (4) Target Protein Ligand-Linker Conjugates (1) Thymidylate Synthase (1) Tyrosinase (1) ULK (2) VEGFR (8) Wee1 (1) α-synuclein (1) β-catenin (1)
By Research Areas:	Cancer (125) Cardiovascular Disease (1) Endocrinology (1) Infection (8) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (10)

By Targets:

Bcr-Abl (116)

AAK1 (1)

Ack1 (1)

Akt (4)

Antibiotic (1)

Apoptosis (25)

Aurora Kinase (13)

Autophagy (28)

Bacterial (1)

Btk (1)

c-Fms (1)

c-Kit (15)

c-Met/HGFR (2)

c-Myc (1)

CaMK (1)

Casein Kinase (1)

Caspase (1)

CDK (2)

Collagen (1)

Cyclin G-associated Kinase (GAK) (1)

Discoidin Domain Receptor (2)

DNA-PK (1)

Drug Metabolite (3)

DYRK (1)

EGFR (5)

Ephrin Receptor (3)

ERK (1)

Ferroptosis (2)

FGFR (9)

FLT3 (10)

GSK-3 (2)

Histone Methyltransferase (1)

IGF-1R (1)

Isotope-Labeled Compounds (6)

JAK (10)

LIM Kinase (LIMK) (2)

LRRK2 (1)

MAP4K (2)

MAPKAPK2 (MK2) (1)

Microtubule/Tubulin (1)

MNK (1)

mTOR (1)

NF-κB (1)

P-glycoprotein (1)

p38 MAPK (3)

PARP (1)

PDGFR (22)

PERK (1)

PI3K (1)

PKD (2)

Prion Protein (3)

PROTACs (3)

Pyk2 (1)

Raf (2)

Reference Standards (15)

RET (2)

Salt-inducible Kinase (SIK) (2)

SARS-CoV (6)

Src (35)

STAT (10)

TAM Receptor (4)

Target Protein Ligand-Linker Conjugates (1)

Thymidylate Synthase (1)

Tyrosinase (1)

ULK (2)

VEGFR (8)

Wee1 (1)

α-synuclein (1)

β-catenin (1)

By Research Areas:

Cancer (125)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (8)

Inflammation/Immunology (7)

Metabolic Disease (1)

Neurological Disease (10)

139

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

GMP Molecules

Targets Recommended: Bcr-Abl

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15463

Imatinib Maximum Cited Publications 120 Publications Verification STI571; CGP-57148B	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits *BCR/ABL, v-Abl, PDGFR* and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-12047

Ponatinib 45+ Cited Publications AP24534	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for *Abl, PDGFRα, VEGFR2, FGFR1, and Src*, respectively .

HY-10159

Nilotinib 45+ Cited Publications AMN107	Bcr-Abl Autophagy	Cancer
Nilotinib is an orally available *Bcr-Abl* tyrosine kinase inhibitor with antineoplastic activity.

HY-10158

Bosutinib 20+ Cited Publications SKI-606	Src Bcr-Abl Autophagy	Cancer
Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC₅₀ of 1.2 nM and 1 nM, respectively .

HY-50946

Imatinib Mesylate Maximum Cited Publications 120 Publications Verification STI571 Mesylate; CGP-57148B Mesylate	c-Kit Bcr-Abl PDGFR Autophagy	Infection Neurological Disease Inflammation/Immunology Cancer
Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, *Bcr-Abl, and PDGFR* (IC₅₀=100 nM) tyrosine kinases.

HY-108766

Ponatinib hydrochloride 45+ Cited Publications AP24534 hydrochloride	Bcr-Abl FGFR PDGFR VEGFR Src Autophagy	Infection Cancer
Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for *Abl, PDGFRα, VEGFR2, FGFR1, and Src*, respectively .

HY-10159A

Nilotinib monohydrochloride monohydrate 45+ Cited Publications AMN107 monohydrochloride monohydrate	Bcr-Abl Autophagy	Cancer
Nilotinib monohydrochloride monohydrate is a second generation tyrosine kinase inhibitor (TKI), is significantly potent against *BCR-ABL, and is active against many BCR-ABL* mutants.

HY-10339

KW-2449 5+ Cited Publications	FLT3 FGFR Bcr-Abl Aurora Kinase Apoptosis	Cancer
KW-2449 is a multi-targeted kinase inhibitor of FLT3, *ABL, ABL* ^T315I and Aurora kinase with IC₅₀s of 6.6, 14, 4 and 48 nM, respectively.

HY-10395

PD173955 1 Publications Verification	Bcr-Abl Src	Cancer
PD173955 is an orally active inhibitor of Src (IC₅₀= 22 nM), Yes, *Abl, ATP* and MAP kinases. PD173955 can effectively prevent the mitotic process and has anticancer activity .

HY-147414

Vamotinib PF-114	Bcr-Abl	Cancer
Vamotinib (PF-114) is a potent, selective and orally active tyrosine kinase inhibitor. Vamotinib inhibits the autophosphorylation of BCR/ABL and BCR/ABL-T315I. Vamotinib induces apoptosis. Vamotinib shows anti-proliferative and anti-tumor activity. Vamotinib has the potential for the research of resistant philadelphia chromosome-positive (Ph+) leukemia. Vamotinib inhibits ABL series kinases with IC₅₀s of 0.49 nM (ABL), 0.78 nM (ABL ^T315I), 9.5 nM (ABL ^E255K), 2.0 nM (ABL ^F317I), 7.4 nM (ABL ^G250E), 1.0 nM (ABL ^H396P), 2.8 nM (ABL ^M351T), 12 nM (ABL ^Q252H), and 4.1 nM (ABL ^Y253F), respectively . Vamotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-122113

PD173952 1 Publications Verification	Src Bcr-Abl Apoptosis Wee1	Cancer
PD173952 is a tyrosine kinases inhibitor with IC₅₀s of 0.3, 1.7 and 6.6 nM against Lyn, *Abl* and Csk, respectively. PD173952 is also a potent Myt1 kinase inhibitor with a K_i of 8.1 nM. PD173952 induces apoptosis .

HY-10158A

Bosutinib hydrate 20+ Cited Publications SKI-606 hydrate	Src Bcr-Abl	Cancer
Bosutinib hydrate is an oraly activel Src/Abl tyrosine kinase inhibito with IC₅₀ of 1.2 nM and 1 nM, respectively .

HY-10943

GNF-7 2 Publications Verification	Bcr-Abl Ack1	Cancer
GNF-7 is a multikinase inhibitor. GNF-7 is a *Bcr-Abl* inhibitor, with IC₅₀s of 133 nM and 61 nM for Bcr-Abl ^WT and Bcr-Abl ^T315I, respectively. GNF-7 also possesses inhibitory activity against both ACK1 (activated CDC42 kinase 1) and GCK (germinal center kinase) with IC₅₀s of 25 nM and 8 nM, respectively. GNF-7 can be used for the research of hematologic malignancies .

HY-148794

Risvodetinib IkT-148009	c-Met/HGFR Bcr-Abl	Neurological Disease Cancer
Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against *c-Abl1, c-Abl2/Arg* with IC₅₀ values of 33 nM, 14 nM, respectively. Risvodetinib suppresses *c-Abl* activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD .

HY-137460

Vodobatinib 2 Publications Verification K0706	Bcr-Abl	Cancer
Vodobatinib (K0706) is a potent, third generation and orally active Bcr-Abl1 tyrosine kinase inhibitor with an IC₅₀ of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants, and has no activity against BCR-ABL1T315I. Vodobatinib can be used for chronic myeloid leukemia (CML) research . Vodobatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-118144

PD166326	Src Bcr-Abl p38 MAPK	Cancer
PD166326 is an orally active tyrosine kinase inhibitor with a IC₅₀ of 8 nM against *abl* tyrosine kinase and a IC₅₀ of 6 nM against src tyrosine kinase. PD166326 blocks *Bcr/Abl* kinase activity. PD166326 inhibits Bcr/Abl-dependent proliferation and cell cycle progression. PD166326 reduces peripheral blood granulocytosis, alleviates splenomegaly and prolongs survival in a mouse model of chronic myeloid leukemia. PD166326 can be used in research related to chronic myeloid leukemia .

HY-10181S

Dasatinib-d8 1 Publications Verification BMS-354825-d₈	Bcr-Abl Src Apoptosis Autophagy	Cancer
Dasatinib-d₈ (BMS-354825-d₈) is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.

HY-107447

N-Deshydroxyethyl Dasatinib N-Deshydroxyethyl BMS-354825	Drug Metabolite Target Protein Ligand-Linker Conjugates Bcr-Abl	Inflammation/Immunology Cancer
N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825) is a metabolite of Dasatinib, Dasatinib is a multi-kinase inhibitor that potently inhibits Bcr-Abl, Src family and platelet-derived growth factor receptor kinases. N-Deshydroxyethyl Dasatinib can be used in cancer and immune disease research .

HY-15749

XL228 4 Publications Verification	Aurora Kinase Bcr-Abl IGF-1R Src	Endocrinology Cancer
XL228 is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 5, 3.1, 1.6, 6.1, 2 nM for *Bcr-Abl, Aurora A, IGF-1R, Src* and Lyn, respectively.

HY-15463S1

Imatinib-d4 STI571 d₄; CGP-57148B d₄	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib-d₄ (STI571-d₄) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-103032

*Multi-kinase* inhibitor 1**	PDGFR c-Kit Bcr-Abl	Cancer
Multi-kinase inhibitor 1 is a potent *multi-kinase* inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and *Bcr-abl* .

HY-103274

PD180970	Bcr-Abl Src c-Kit Apoptosis	Neurological Disease Cancer
PD180970 is a highly potent and ATP-competitive p210 ^Bcr-Abl kinase inhibitor, with an IC₅₀ of 5 nM for inhibiting the autophosphorylation of p210 ^Bcr-Abl. PD180970 also inhibits Src and KIT kinase with IC₅₀s of 0.8 nM and 50 nM, respectively. PD180970 indcues apoptosis of K562 leukemic cells, and can be used for chronic myelogenous leukemia research .

HY-12047S

Ponatinib-d8 AP24534-d₈	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib-d₈ (AP24534-d₈) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-P1785

Abl Cytosolic Substrate Abltide	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus .

HY-15463S

Imatinib-d8 1 Publications Verification STI571-d₈; CGP-57148B-d₈	Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-15814

HG-7-85-01	Bcr-Abl PDGFR c-Kit Src JAK Apoptosis	Cancer
HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of *Bcr-Abl, PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl* kinase, KDR and RET with IC₅₀s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC₅₀>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression .

HY-P5426

Abl protein tyrosine kinase substrate	Bcr-Abl	Others
Abl protein tyrosine kinase substrate is a biological active peptide. (Abltide is a peptide substrate for Abl Kinase (Abl protein tyrosine kinase), a partner in the gag-Abl fusion protein of the Abelson murine leukemia virus. Used in Western blot and kinase assay.)

HY-W143698

*PDGFRα kinase* inhibitor 2**	Bcr-Abl c-Kit PDGFR	Cancer
PDGFRα kinase inhibitor 2 (compound 1), an Imatinib (HY-15463) analogue, is a covalent and irreversible kinase inhibitor with IC₅₀s of 6.95 μM, 2.45 μM, 1.39 μM for *ABL1* wt, KIT wt, PDGFRR wt .

HY-12083

PPY-A	Bcr-Abl	Cancer
PPY-A is a potent T315I mutant and wild-type *Abl* kinases inhibitor with IC₅₀s of 9 and 20 nM, respectively. PPY-A inhibits Ba?F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC₅₀s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML) .

HY-117718

AG957 Tyrphostin AG957; NSC 654705	Bcr-Abl	Cancer
AG957 (Tyrphostin AG957;NSC 654705) is a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity . AG957 is a *bcr/abl* kinase inhibitor with an IC₅₀ of 2.9 μM for p210 ^bcr/abl autokinase activity .

HY-10159S

Nilotinib-d6 AMN107-d₆	Bcr-Abl Autophagy	Cancer
Nilotinib-d₆ is a deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity .

HY-176461

Pro-Dasatinib	Src Bcr-Abl	Cancer
Pro-Dasatinib (compound 2j), an amino acid analog of Dasatinib (HY-10181), is a potent *Src/Abl* kinase inhibitor. Pro-Dasatinib has antiproliferative activity against K652 leukemia cancer cells with an IC₅₀ of 0.21 nM.

HY-108766R

Ponatinib hydrochloride (Standard) AP24534 hydrochloride (Standard)	Bcr-Abl FGFR PDGFR VEGFR Src Autophagy Reference Standards	Infection Cancer
Ponatinib (hydrochloride) (Standard) is the analytical standard of Ponatinib (hydrochloride). This product is intended for research and analytical applications. Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively .

HY-10159C

Nilotinib hydrochloride dihydrate 45+ Cited Publications AMN107 hydrochloride dihydrate	Autophagy Bcr-Abl	Cancer
Nilotinib (AMN107) hydrochloride dihydrate is an orally active *Bcr-Abl* tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia .

HY-15463R

Imatinib (Standard) STI571 (Standard); CGP-57148B (Standard)	Reference Standards Bcr-Abl PDGFR c-Kit SARS-CoV Autophagy	Cancer
Imatinib (Standard) is the analytical standard of Imatinib. This product is intended for research and analytical applications. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits *BCR/ABL, v-Abl, PDGFR* and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-145887

BCR-ABL1-IN-1	Bcr-Abl	Cancer
BCR-ABL1-IN-1 (Example 74) is the inhibitor for ABL1 (64-515) with IC₅₀ of 8.7 nM. BCR-ABL1-IN-1 can be used in research on diseases related to the central nervous system (CNS) .

HY-101034

CHMFL-ABL/KIT-155 CHMFL-Abl-KIT-155	Bcr-Abl c-Kit Apoptosis PDGFR Discoidin Domain Receptor	Cancer
CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC₅₀s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC₅₀=81 nM), CSF1R (IC₅₀=227 nM), DDR1 (IC₅₀=116 nM), DDR2 (IC₅₀=325 nM), LCK (IC₅₀=12 nM) and PDGFRβ (IC₅₀=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis .

HY-10159R

Nilotinib (Standard) AMN107 (Standard)	Reference Standards Bcr-Abl Autophagy	Cancer
Nilotinib (Standard) is the analytical standard of Nilotinib. This product is intended for research and analytical applications. Nilotinib is an orally available *Bcr-Abl* tyrosine kinase inhibitor with antineoplastic activity.

HY-10159B

Nilotinib hydrochloride 45+ Cited Publications AMN107 hydrochloride	Bcr-Abl Autophagy	Cancer
Nilotinib (AMN107) hydrochloride is an orally active *Bcr-Abl* tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia .

HY-E70634

**ABL1 E255K Recombinant Human Active Protein Kinase**	Bcr-Abl	Cancer
The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate (HY-50946) binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 E255K Recombinant Human Active Protein Kinase is a recombinant ABL1 E255K protein that can be used to study ABL1 E255K-related functions .

HY-12047R

Ponatinib (Standard) AP24534 (Standard)	Reference Standards Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (Standard) is the analytical standard of Ponatinib. This product is intended for research and analytical applications. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for *Abl, PDGFRα, VEGFR2, FGFR1, and Src*, respectively .

HY-119370

CHMFL-ABL-121	Bcr-Abl Apoptosis	Cancer
CHMFL-ABL-121 is a highly potent type II **ABL kinase inhibitor with IC₅₀*s of 2 nM and 0.2 nM against purified inactive ABL* wt and T315I kinase protein, respectively .

HY-18819

BCR-ABL-IN-2	Bcr-Abl	Cancer
BCR-ABL-IN-2 is an inhibitor of *BCR-ABL1* tyrosine kinase, with IC₅₀s of 57 nM, 773 nm for ABL1 ^native and ABL1 ^T315I, respectively.

HY-10364

AP24163	Bcr-Abl	Cancer
AP24163 is a *BCR-ABL* kinase inhibitor. AP24163 inhibits wild-type (native) *BCR-ABL* and *BCR-ABL-T315I* with IC₅₀ values of 7 nM and 511 nM, respectively. AP24163 can be used in the research of chronic myeloid leukemia (CML) .

HY-179247

BCR-ABL1-IN-2	Bcr-Abl	Cancer
BCR-ABL1-IN-2 (compound 8) is a potent BCR-ABL1 tyrosine kinase inhibitor. BCR-ABL1-IN-2 exhibits activity in Imatinib (HY-15463) resistant K562/DOX cells with LC₅₀ of 5.29 μM. BCR-ABL1-IN-2 shows no significant toxicity in nontumor cells. BCR-ABL1-IN-2 can be used for chronic myeloid leukemia research .

HY-176269

VS1150	Bcr-Abl ERK STAT PARP Caspase Apoptosis	Cancer
VS1150 (Compound 11) is a *BCR-ABL*-targeting phosphorylation-inducing chimeric small molecule (PHICS). VS1150 significantly inhibits oncogenic kinase BCR-ABL signaling by inducing inhibitory phosphorylation at its Y253 (EC₅₀: 69 nM), subsequently triggering cell apoptosis. VS1150 also inhibits other oncogenic ABL fusions and drug-resistant mutants like T315I. VS1150 can be used for chronic myeloid leukemia (CML) and other ABL fusion-driven cancers research .

HY-50946R

Imatinib Mesylate (Standard) STI571 Mesylate (Standard); CGP-57148B Mesylate (Standard)	Reference Standards c-Kit Bcr-Abl PDGFR Autophagy	Cancer
Imatinib (Mesylate) (Standard) is the analytical standard of Imatinib (Mesylate). This product is intended for research and analytical applications. Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, *Bcr-Abl, and PDGFR* (IC₅₀=100 nM) tyrosine kinases.

HY-10057

AT9283 hydrochloride	Aurora Kinase	Cancer
AT9283 hydrochloride is a multi-targeted kinase inhibitor with anti-tumor activity. AT9283 hydrochloride has been found to effectively inhibit Aurora A and Aurora B kinases, thereby affecting cell proliferation and survival. AT9283 hydrochloride can also inhibit several other kinases, including JAK2 and Abl (T315I) .

HY-112314

AZD0424	Src Bcr-Abl Apoptosis	Cancer
AZD0424 is an orally active, and dual selective *Src/Abl* kinase inhibitor with potential antineoplastic activity . AZD0424 induces apoptosis and cell cycle arrest in lymphoma cells .

HY-15463S3

Imatinib-13C,d3 STI571-¹³C,d₃; CGP-57148B-¹³C,d₃	Isotope-Labeled Compounds Autophagy SARS-CoV Bcr-Abl PDGFR c-Kit	Cancer
Imatinib- ¹³C,d₃ (STI571- ¹³C,d₃) is ¹³C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits *BCR/ABL, v-Abl, PDGFR* and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

Cat. No.	Product Name

HY-L196

Protein Kinase Compound Library

4,400 compounds

Protein Kinases (PTKs) are a class of phosphotransferases that phosphorylate proteins. Protein kinases participate in many signal transduction pathways including those involved with growth, differentiation, and cell division. Protein kinase not only plays an important role in the process of cell activation, but also its abnormal expression is closely related to the pathogenesis of many diseases. So far, the protein kinase family has become one of the most important drug targets. The most common drug targets include ALK, B-Raf, BCR-Abl, EGFR, and VEGFR.

MCE designs a unique collection of 4,400 bioactive compounds targeting protein kinases, which is an important tool for the development of drug targeting protein kinases.

HY-L016

Protein Tyrosine Kinase Compound Library

1,586 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,586 compounds that act as a useful tool for PTKs-related drug screening and disease research.

Cat. No.	Product Name	Type

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)

Fluorescent Dyes

Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

HY-12292G

IM-12

Fluorescent Dyes

IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS and COX-2, and induces ER stress, Ca ²⁺ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABL ^T315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia .

Cat. No.	Product Name	Type

HY-15150G

Bemcentinib (GMP)

R428 (GMP); BGB324 (GMP)

Biochemical Assay Reagents

HY-12292G

IM-12

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P1785

Abl Cytosolic Substrate Abltide	Bcr-Abl	Cancer
Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ). Abl Protein Tyrosine Kinase (AbI) is a truncated form of the v-AbI Protein Tyrosine Kinase, a partner in the Gag-Abl fusion protein of the Abelson murine leukemia virus .

HY-P5426

Abl protein tyrosine kinase substrate	Bcr-Abl	Others
Abl protein tyrosine kinase substrate is a biological active peptide. (Abltide is a peptide substrate for Abl Kinase (Abl protein tyrosine kinase), a partner in the gag-Abl fusion protein of the Abelson murine leukemia virus. Used in Western blot and kinase assay.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-108486

Herbimycin A	Infection Quinones Microorganisms Classification of Application Fields Benzene Quinones Disease Research Fields Source Classification	Bacterial Antibiotic
Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60 ^v-src and p210 ^BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.

HY-N14635

Paeciloquinone A	Microorganisms Xanthones Phenols Source Classification	EGFR
Paeciloquinone A can inhibit EGFR protein tyrosine kinase. Paeciloquinone A inhibits the *V-abl* protein tyrosine** kinase with an IC₅₀ of 0.59 μM .

HY-N14637

Paeciloquinone C	Microorganisms Xanthones Phenols Source Classification	EGFR
Paeciloquinone C can inhibit the EGFR protein tyrosine kinase. Paeciloquinone C inhibits the V-abl protein tyrosine *K_i*nase with an IC₅₀ of 0.56 μM .

Species:	Human (6)
Tag:	Tag Free (4) GST (2)
Source:	sf9 insect cells (3) Sf9 insect cells (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P71685

	ABL1 Protein, Human (GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	E. coli
	ABL1, Human (GST) is a non-receptor tyrosine-protein kinase. ABL1, Human is implicated in a wide range of cellular processes, including regulation of cell growth and survival, oxidative stress and DNA-damage responses, actin dynamics and cell migration, transmission of information about the cellular environment through integrin signaling.

HY-P702716

	ABL1 Protein, Human (Active, sf9) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	Sf9 insect cells
	ABL1 is a non-receptor tyrosine protein kinase that coordinates key cellular processes for growth and survival. It affects cytoskeletal remodeling, cell motility, and receptor endocytosis. ABL1 Protein, Human (sf9) is the recombinant human-derived ABL1, expressed by Sf9 insect cells, with tag-free. The total length of ABL1 Protein, Human (sf9) is 1104 a.a..

HY-P77308

	ABL1 Protein, Human (Active, sf9, GST) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	Sf9 insect cells
	ABL1 is a non-receptor tyrosine protein kinase that coordinates key cellular processes for growth and survival. It affects cytoskeletal remodeling, cell motility, and receptor endocytosis. ABL1 Protein, Human (sf9, GST) is the recombinant human-derived ABL1 protein, expressed by Sf9 insect cells , with N-GST labeled tag.

HY-P705723

	ABL1 Protein, Human (Active, Y245F, sf9) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	sf9 insect cells

HY-P705725

	ABL1 Protein, Human (Inactive, K290R, sf9) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	sf9 insect cells

HY-P705724

	ABL1 Protein, Human (Active, Y245F, Y412F, sf9) Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine protein kinase 1; Abl 1; Abl; JTK7; p150; Proto oncogene tyrosine protein kinase Abl1	Human	sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10181S

Dasatinib-d8 1 Publications Verification
Dasatinib-d₈ (BMS-354825-d₈) is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.

HY-15463S1

Imatinib-d4
Imatinib-d₄ (STI571-d₄) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-12047S

Ponatinib-d8
Ponatinib-d₈ (AP24534-d₈) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-15463S

Imatinib-d8 1 Publications Verification
Imatinib-d₈ is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity .

HY-10159S

Nilotinib-d6
Nilotinib-d₆ is a deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity .

HY-15463S3

Imatinib-13C,d3

Imatinib- ¹³C,d₃ (STI571- ¹³C,d₃) is ¹³C labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .

HY-15463S2

Imatinib-d3 hydrochloride

Imatinib-d₃ (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

HY-132549S

Nilotinib-d3
Nilotinib-d₃ is the deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity .

HY-10159S1

Nilotinib-13C,d3
Nilotinib-13C,d3 is a deuterated labeled Nilotinib . Nilotinib is an orally available *Bcr-Abl* tyrosine kinase inhibitor with antineoplastic activity.

HY-10158S1

Bosutinib-13C,d3
Bosutinib- ¹³C,d₃ (SKI-606- ¹³C,d₃) is ¹³C labeled Bosutinib. Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC₅₀ of 1.2 nM and 1 nM, respectively .

HY-15728S

Radotinib-d6

Radotinib-d₆ is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases .

HY-15150S

Bemcentinib-d8

Bemcentinib-d₈ (R428-d₈) is the deuterium labeled Bemcentinib (HY-15150). Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC₅₀ of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .

Host:	Mouse (2) Rabbit (4)
Reactivity:	Human (6) Rat (2) Mouse (5)
Application:	IHC-P (2) ICC/IF (4) IP (1) WB (4) FC (3) ELISA (3)
Isotype:	IgG (3) IgG/Kappa (1)
Conjugation:	Non-conjugated (6)
Clonality:	Monoclonal (4) Recombinant (2)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86379

	ABL1 Antibody (YA6071) c-Abl; Abl1; Abl; JTK7; Tyrosine-protein kinase Abl1; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-Abl; p150;	WB, IHC-P, ICC/IF, IP, ELISA	Human
	ABL1 Antibody (YA6071) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ABL1.

HY-P85070

	ABL1 Antibody (YA4762) Abl1; Abl; JTK7; Tyrosine-protein kinase Abl1; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-Abl; p150	WB, IHC-P, ICC/IF, FC	Human, Mouse
	ABL1 Antibody (YA4762) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to ABL1.

HY-P83458

	ABL2 Antibody (YA3203) Abl2; AblL; ARG; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; Abelson-related gene protein; Tyrosine-protein kinase ARG	WB, FC	Human, Mouse, Rat
	ABL2 Antibody (YA3203) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ABL2.

HY-P85044

	ABL2 Antibody (YA4736) Abl2; AblL; ARG; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; Abelson-related gene protein; Tyrosine-protein kinase ARG	ICC/IF, ELISA	Human, Mouse
	ABL2 Antibody (YA4736) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to ABL2.

HY-P83458A

	ABL2 Antibody (YA3203)(PBS only) Abl2; AblL; ARG; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; Abelson-related gene protein; Tyrosine-protein kinase ARG	WB, FC	Human, Mouse, Rat
	ABL2 Antibody (YA3203) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ABL2.

HY-P85044A

	ABL2 Antibody (YA4736)(PBS only) Abl2; AblL; ARG; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; Abelson-related gene protein; Tyrosine-protein kinase ARG	ICC/IF, ELISA	Human, Mouse
	ABL2 Antibody (YA4736) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to ABL2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Targets Recommended: Bcr-Abl

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12292G

IM-12	NF-κB STAT GSK-3 β-catenin Bcr-Abl	Cancer
IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of *p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS* and COX-2, and induces ER stress, Ca ²⁺ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABL ^T315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Abl kinase

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

GMP Molecules

Natural
Products